product summary
Loading...
company name :
R&D Systems
product type :
protein
product name :
Recombinant Mouse Osteoprotegerin/TNFRSF11B Fc Chimera, CF
catalog :
459-MO-100
quantity :
100 ug
price :
388 USD
more info or order :
R&D Systems product webpage
citations: 22
Reference
AlQranei M, Senbanjo L, Aljohani H, Hamza T, Chellaiah M. Lipopolysaccharide- TLR-4 Axis regulates Osteoclastogenesis independent of RANKL/RANK signaling. BMC Immunol. 2021;22:23 pubmed publisher
Paolino M, Koglgruber R, Cronin S, Uribesalgo I, Rauscher E, Harreiter J, et al. RANK links thymic regulatory T cells to fetal loss and gestational diabetes in pregnancy. Nature. 2021;589:442-447 pubmed publisher
Tong X, Chen M, Song R, Zhao H, Bian J, Gu J, et al. Overexpression of c-Fos reverses osteoprotegerin-mediated suppression of osteoclastogenesis by increasing the Beclin1-induced autophagy. J Cell Mol Med. 2021;25:937-945 pubmed publisher
Adhyatmika A, Beljaars L, Putri K, Habibie H, Boorsma C, Reker Smit C, et al. Osteoprotegerin is More than a Possible Serum Marker in Liver Fibrosis: A Study into its Function in Human and Murine Liver. Pharmaceutics. 2020;12: pubmed publisher
Hasegawa T, Kikuta J, Sudo T, Matsuura Y, Matsui T, Simmons S, et al. Identification of a novel arthritis-associated osteoclast precursor macrophage regulated by FoxM1. Nat Immunol. 2019;20:1631-1643 pubmed publisher
Gao X, Zheng J, Tu S, Cai B, Zeng R, Xiang L. Role of osteoprotegerin in the regulation of dental epithelial‑mesenchymal signaling during tooth development. Mol Med Rep. 2019;20:3035-3042 pubmed publisher
Dufresne S, Boulanger Piette A, Bossé S, Argaw A, Hamoudi D, Marcadet L, et al. Genetic deletion of muscle RANK or selective inhibition of RANKL is not as effective as full-length OPG-fc in mitigating muscular dystrophy. Acta Neuropathol Commun. 2018;6:31 pubmed publisher
Barrott J, Illum B, Jin H, Hedberg M, Wang Y, Grossmann A, et al. Paracrine osteoprotegerin and β-catenin stabilization support synovial sarcomagenesis in periosteal cells. J Clin Invest. 2018;128:207-218 pubmed publisher
Bernardi S, Toffoli B, Bossi F, Candido R, Stenner E, Carretta R, et al. Circulating osteoprotegerin is associated with chronic kidney disease in hypertensive patients. BMC Nephrol. 2017;18:219 pubmed publisher
Ealba E, Jheon A, Hall J, Curantz C, Butcher K, Schneider R. Neural crest-mediated bone resorption is a determinant of species-specific jaw length. Dev Biol. 2015;408:151-63 pubmed publisher
Matsushita M, Ozaki Y, Hasegawa Y, Terada F, Tabata N, Shiheido H, et al. A novel phthalimide derivative, TC11, has preclinical effects on high-risk myeloma cells and osteoclasts. PLoS ONE. 2015;10:e0116135 pubmed publisher
Mukai T, Ishida S, Ishikawa R, Yoshitaka T, Kittaka M, Gallant R, et al. SH3BP2 cherubism mutation potentiates TNF-?-induced osteoclastogenesis via NFATc1 and TNF-?-mediated inflammatory bone loss. J Bone Miner Res. 2014;29:2618-35 pubmed publisher
Takeshita S, Fumoto T, Naoe Y, Ikeda K. Age-related marrow adipogenesis is linked to increased expression of RANKL. J Biol Chem. 2014;289:16699-710 pubmed publisher
Rementer C, Wu M, Buranaphatthana W, Yang H, Scatena M, Giachelli C. An inducible, ligand-independent receptor activator of NF-?B gene to control osteoclast differentiation from monocytic precursors. PLoS ONE. 2013;8:e84465 pubmed publisher
Charles J, Hsu L, Niemi E, Weiss A, Aliprantis A, Nakamura M. Inflammatory arthritis increases mouse osteoclast precursors with myeloid suppressor function. J Clin Invest. 2012;122:4592-605 pubmed publisher
Onal M, Xiong J, Chen X, Thostenson J, Almeida M, Manolagas S, et al. Receptor activator of nuclear factor ?B ligand (RANKL) protein expression by B lymphocytes contributes to ovariectomy-induced bone loss. J Biol Chem. 2012;287:29851-60 pubmed publisher
Schrader J, Rennekamp W, Niebergall U, Schoppet M, Jahr H, Brendel M, et al. Cytokine-induced osteoprotegerin expression protects pancreatic beta cells through p38 mitogen-activated protein kinase signalling against cell death. Diabetologia. 2007;50:1243-7 pubmed
Nakamichi Y, Udagawa N, Kobayashi Y, Nakamura M, Yamamoto Y, Yamashita T, et al. Osteoprotegerin reduces the serum level of receptor activator of NF-kappaB ligand derived from osteoblasts. J Immunol. 2007;178:192-200 pubmed
Berry J, Ealba E, Pettway G, Datta N, Swanson E, Somerman M, et al. JunB as a downstream mediator of PTHrP actions in cementoblasts. J Bone Miner Res. 2006;21:246-57 pubmed
Gustafsson B, Thommesen L, Stunes A, Tommeras K, Westbroek I, Waldum H, et al. Serotonin and fluoxetine modulate bone cell function in vitro. J Cell Biochem. 2006;98:139-51 pubmed
Bengtsson A, Ryan E, Giordano D, Magaletti D, Clark E. 17beta-estradiol (E2) modulates cytokine and chemokine expression in human monocyte-derived dendritic cells. Blood. 2004;104:1404-10 pubmed
Cao J, Venton L, Sakata T, Halloran B. Expression of RANKL and OPG correlates with age-related bone loss in male C57BL/6 mice. J Bone Miner Res. 2003;18:270-7 pubmed
product information
brand :
R&D Systems
master code :
459-MO
SKU :
459-MO-100
product name :
Recombinant Mouse Osteoprotegerin/TNFRSF11B Fc Chimera, CF
unit size :
100 ug
description :
Thioredoxin reductase inhibitor; induces MPT
target :
Osteoprotegerin/TNFRSF11B
category :
Proteins and Enzymes
alt names :
OCIF, OCIFMGC29565, OPG, OPGtumor necrosis factor receptor superfamily member 11B, Osteoclastogenesis inhibitory factor, Osteoprotegerin, TNFRSF11B, TR1, tumor necrosis factor receptor superfamily, member 11b
buffer :
Lyophilized from a 0.2 µm filtered solution in PBS.
conjugate :
Unconjugated
all available conjugate :
Unconjugated
purity :
>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
species :
Mouse
storage :
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 3 months, -20 to -70 °C under sterile conditions after reconstitution.
observed molecular weight :
85-95 kDa, reducing conditions
theoretical molecular weight :
70.9 kDa (monomer)
gene symbol :
Tnfrsf11b
details of functionality :
Measured by its ability to inhibit TRAIL-mediated cytotoxicity using L-929 mouse fibroblast cells treated with TRAIL. The ED50 for this effect is 3-15 ng/mL in the presence of 12 ng/mL of cross-linked Recombinant Human TRAIL/TNFSF10 (Catalog #s 375-TL and MAB050 ).
endotoxin note :
<0.10 EU per 1 µg of the protein by the LAL method.
accessionNumbers :
Q6PI12
applications :
Bioactivity
source :
NS0-derived Recombinant Mouse Osteoprotegerin/TNFRSF11B Fc Chimera, CF
USD :
359
Jul-22 :
388 USD
sizes available :
100 ug
more info or order :
R&D Systems product webpage
company information
R&D Systems
614 McKinley Place N.E.
Minneapolis, MN 55413
info@RnDSystems.com
https://www.rndsystems.com
800 343-7475
headquarters: USA
R&D Systems develops and manufactures high-quality proteins and serves as a world leader in immunoassays. R&D Systems also produces quality antibodies, antibody arrays, stem cell and cell culture products, and cell selection and detection products, serving the life science and diagnostics industry.